RA Capital Management, RTW Investments and Janus Henderson Investors led a $175m Series B round in Aktis Oncology.

RA Capital Management, RTW Investments and Janus Henderson Investors led a $175m Series B round in Aktis Oncology, a clinical-stage biotechnology company pioneering the discovery and development of novel targeted alpha radiopharmaceuticals, with participation from T. Rowe Price Associates, Avidity Partners, Bristol Myers Squibb, Eli Lilly and Company, and MRL Ventures Fund. "The overwhelming support from high caliber investors underscores the progress we have made on our pipeline, platform, and supply chain capabilities, exemplified by the significant opportunity for AKY-1189, our first-in-class miniprotein alpha radioconjugate targeting Nectin-4 in development for several tumor types. With over $300m in cash, we are well-positioned to prosecute several opportunities to expand the benefit of this exciting modality into new patient populations," Matthew Roden, Aktis Oncology President and CEO.